Aktis Oncology, Inc.

NASDAQ: AKTS · Healthcare · Biotechnology

PublicHQ Boston, MA · SuffolkCIK 0002035832Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 48

v0.1 · 5/100 weight · pillars only

↑ Altman-Z, market scale · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

$10.1M

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

as of 2026-09-13

Market cap

$1.4B

as of 2026-09-13

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Aktis Oncology, Inc.’s financial profile?

Aktis Oncology, Inc. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

First Tracks Biotherapeutics Inc——ArriVent BioPharma, Inc.——Latigo Biotherapeutics Inc.——LB Pharmaceuticals Inc Common Stock——ORIC Pharmaceuticals, Inc.——Seaport Therapeutics, Inc. Common Stock——

Neighbors

Suffolk →

Vertex Pharmaceuticals Incorporated$12.0B88A American Tower Corporation$935.9M76B+State Street Corporation$13.9B67B NSTAR Electric Company——Toast, Inc.$6.2B67B PTC Inc.$2.7B83B+

Key facts

CEOMatthew Roden

SectorHealthcare

IndustryBiotechnology

HeadquartersBoston, MA

ExchangeNASDAQ: AKTS

Employees79

IPO date2026-01-09

Latest filings

8-K2026-08-13 10-Q2026-08-13 10-Q2026-05-11 8-K2026-05-11 8-K2026-04-16 10-K2026-03-30 8-K2026-03-30 8-K2026-01-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.